Economic implications of biological therapy for Crohn’s disease

Paweł W. Petryszyn; Leszek Paradowski

doi:10.5114/pg.2015.55749

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2015
vol. 10

Send email

Copy url:

abstract:

Review paper

Economic implications of biological therapy for Crohn’s disease

Paweł W. Petryszyn

,

Leszek Paradowski

Prz Gastroenterol 2015; 10 (4): 197–202

DOI: https://doi.org/10.5114/pg.2015.55749

Online publish date: 2015/11/23

View full text Get citation

PlumX metrics:

In the early 90s American authors estimated that if a theoretical new drug was introduced that was capable of changing the natural course of the disease and reducing direct non-drug medical costs (including hospitalisation and surgery) by 20%, despite doubling the overall drugs bill, there would still be a reduction in total direct medical costs of Crohn’s disease by 13%. Infliximab proved to be efficacious in reducing and maintaining remission in moderate to severe active Crohn’s disease and/or fistulising Crohn’s disease. A higher acquisition cost still remains its major limitation. Currently only the use of infliximab in case of treatment for flares seems to be cost-effective. However, this statement may be modified in the near future.

keywords:

Economic implications of biological therapy for Crohn’s disease

Paweł W. Petryszyn , Leszek Paradowski

Crohn’s disease, biological therapy, medical economics

Paweł W. Petryszyn

,

Leszek Paradowski